PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,391.60% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,391.60% | -- | -- | -- | -- |
| Cost of Revenue | 1,257.98% | -- | -- | -- | -- |
| Gross Profit | 1,652.70% | -- | -- | -- | -- |
| SG&A Expenses | 174.49% | 402.09% | 349.47% | 1,004.35% | 601.13% |
| Depreciation & Amortization | 731.10% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 421.46% | 1,470.07% | 1,520.83% | 1,584.89% | 822.68% |
| Operating Income | 45.94% | 194.81% | 243.68% | -746.58% | -522.68% |
| Income Before Tax | 62.10% | 267.98% | 377.03% | -852.39% | -744.94% |
| Income Tax Expenses | 57,200.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.79% | 217.98% | 425.17% | -853.19% | -744.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00% | -- | -- | -- | -- |
| Net Income | 36.24% | 212.25% | 441.35% | -851.46% | -747.08% |
| EBIT | 45.94% | 194.81% | 243.68% | -746.58% | -522.68% |
| EBITDA | 72.60% | -- | -- | -- | -- |
| EPS Basic | 69.23% | 120.27% | 158.97% | -70.27% | -212.00% |
| Normalized Basic EPS | 81.63% | 128.26% | 153.06% | -69.57% | -206.25% |
| EPS Diluted | 69.23% | 120.27% | 158.97% | -70.27% | -212.00% |
| Normalized Diluted EPS | 81.63% | 128.26% | 153.06% | -69.57% | -206.25% |
| Average Basic Shares Outstanding | 110.80% | 468.56% | 479.64% | 458.02% | 174.39% |
| Average Diluted Shares Outstanding | 110.80% | 468.56% | 479.64% | 458.02% | 174.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |